Aclarion, Inc. Comments on Echo Lake Capital's Letter and Unsolicited Proposal
Stocks in this Quantisnow insightHealth Care
Historical context for ACON
Across the 23 sessions after earlier ACON headlines, the stock closed higher 12 times and lower 9 times, with a median move of 3.3% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | ACON | SPY |
|---|---|---|---|
| May 28, 2026 | Echo Lake Capital Offers To Acquire Aclarion Inc. | +1.0% | +0.6% |
| May 7, 2026 | Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment | -3.7% | -0.3% |
| May 6, 2026 | Aclarion Announces Inducement Grant to New Commercial Director, Western U.S. | +2.5% | +1.4% |
| May 5, 2026 | Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine | -3.3% | +0.8% |
| Apr 30, 2026 | Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption | +1.8% | +1.0% |
| Apr 28, 2026 | Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of Nociscan | +0.0% | -0.5% |
Quantisnow market dataNASDAQ
ACON
Aclarion Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Medical Specialities
- Listed since
- 2022
Get push alerts for ACON
Full ACON profile on Quantisnow Follow ACON and get a push notification the moment its next story breaks.